iData Insights

Myocardial Fibrosis - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 30, 2016 12:35 IST

Myocardial Fibrosis - Pipeline Review, H2 2015 Summary Global Markets Direct s, Myocardial Fibrosis - Pipeline Review, H2 2015, provides an overview of the Myocardial Fibrosiss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myocardial Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Fibrosis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocardial Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocardial Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocardial Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myocardial Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myocardial Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 6

Global Markets Direct Report Coverage 6

Myocardial Fibrosis Overview 7

Therapeutics Development 8

Pipeline Products for Myocardial Fibrosis - Overview 8

Pipeline Products for Myocardial Fibrosis - Comparative Analysis 9

Myocardial Fibrosis - Therapeutics under Development by Companies 10

Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes 11

Myocardial Fibrosis - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Myocardial Fibrosis - Products under Development by Companies 14

Myocardial Fibrosis - Products under Investigation by Universities/Institutes 15

Myocardial Fibrosis - Companies Involved in Therapeutics Development 16

AstraZeneca Plc 16

BioLineRx, Ltd. 17

Digna Biotech, S.L. 18

Evotec AG 19

Galectin Therapeutics, Inc. 20

GTx, Inc. 21

MandalMed, Inc. 22

miRagen Therapeutics, Inc. 23

ProMetic Life Sciences Inc. 24

Virocan Therapeutics Private Limited 25

Myocardial Fibrosis - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

AmVicf-006 - Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

AZ-876 - Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

CGEN-856 - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

disitertide - Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Drugs for Tissue Fibrosis - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Galectin-3C - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

GM-CT-01 - Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

GRMD-02 - Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

GTx-878 - Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

MGN-4220 - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

P-17 - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

PBI-4050 - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Small Molecule for Cardiac Fibrosis and Heart Failure - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

SP-20102 - Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

TM-5441 - Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Myocardial Fibrosis - Recent Pipeline Updates 59

Myocardial Fibrosis - Dormant Projects 73

Myocardial Fibrosis - Product Development Milestones 74

Featured News & Press Releases 74

Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe 74

Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 74

Appendix 76

Methodology 76

Coverage 76

Secondary Research 76

Primary Research 76

Expert Panel Validation 76

Contact Us 76

Disclaimer 77

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects